We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against the other hot stocks.
While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, dockworkers from the International Longshoremen’s Association (ILA) have gone on strike at major U.S. ports along the East and Gulf coasts, marking the first such strike in nearly 50 years. The dispute involves a six-year contract covering 25,000 workers, with the ILA demanding significant wage increases and addressing concerns over automation.
While the US Maritime Alliance has offered wage and pension boosts, negotiations have still stalled. The strike could cause major disruptions to imports, especially food, clothing, and car shipments, with potential economic losses of $4 or $5 billion per week.
Moreover, CBS reported that Hurricane Helene is projected to be one of the most expensive storms in U.S. history, with Moody’s Analytics estimating property damage between $15 and $26 billion. AccuWeather forecasts that the overall damage and economic loss could reach up to $110 billion.
Central Banks, Port Strikes, and Inflation Risks: What Lies Ahead
Deepak Puri, Deutsche Bank Private Bank CIO of the Americas, recently joined CNBC’s ‘Money Movers’ as he discussed the current high expectations in the U.S. economy and noted that while inflation and employment are relatively stable, challenges lie ahead due to factors like the port strike, global conflicts, and post-hurricane reconstruction.
He mentioned that Chicago Fed President, Austan Goolsbee has highlighted the difficulty in maintaining the current economic balance. Puri advises patience in the markets due to various uncertainties, including the upcoming election.
Puri explained that while many central banks are lowering interest rates, it is uncertain whether the U.S. economy will avoid a downturn. Inflation remains a risk, and the U.S. port strike could cause serious economic problems if it lasts long, even though it hasn’t yet impacted the market much. He warned that several issues combined could affect inflation and overall economic performance.
When discussing the balance between inflation and jobs, the CIO said that concerns about the job market were bigger until recently, but now inflation is becoming more of a risk. He highlighted how challenging it is for the Fed to manage this situation, especially as consumer spending remains steady but is shifting. Meanwhile, sectors like housing and manufacturing, which are sensitive to interest rates, will need to take up the slack.
Finally, Puri talked about whether the Fed could pause rate cuts like the European Central Bank did. He thinks the Fed will keep lowering rates, but the size of future cuts will depend on upcoming labor market data.
Our Methodology
For this article, we made a list of the top 55 best-performing stocks on a year-to-date basis with a market cap of over $2 billion, as of October 1. We narrowed our list to 10 stocks that were most favored by analysts. The best hot stocks to buy right now are listed in ascending order of the average price target upside. We also mentioned the hedge fund sentiment around each stock which was taken from Insider Monkey’s database of over 900 elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data.
Janux Therapeutics, Inc. (NASDAQ:JANX)
Number of Hedge Fund Holders: 31
Year-to-Date Share Price Gains: 303.81%
Average Price Target Upside: 49.44%
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company working on cancer treatments that activate the immune system to fight tumors. It has developed two special platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).
The platforms aim to create safe and effective therapies that help the immune system destroy tumors while minimizing side effects. The company is developing a variety of TRACTr and TRACIr treatments for solid tumors.
Right now, it has two TRACTr treatments in clinical trials: one targets Prostate-Specific Membrane Antigen (PSMA) for prostate cancer, and the other targets Epidermal Growth Factor Receptor (EGFR) for colorectal, lung, head and neck, and kidney cancers.
Janux Therapeutics (NASDAQ:JANX) has two primary candidates JANX007 (targeting PSMA for prostate cancer) and JANX008 (targeting EGFR for various solid tumors). The lead candidate, JANX007, is in a Phase 1 trial for metastatic castration-resistant prostate cancer, while JANX008 is also in a Phase 1 trial for various solid tumors.
As of June 30, 2024, the company reported $646.3 million in cash and investments, an increase from $344 million at the end of 2023. The company’s research and development expenses for the second quarter of 2024 remained consistent at $14.9 million, matching the previous year’s figures.
However, general and administrative expenses rose to $7.8 million, up from $6.9 million in 2023. Additionally, Janux (NASDAQ:JANX) experienced a reduced net loss of $6.0 million for the quarter, a significant improvement compared to a net loss of $17.5 million in the same period last year.
Overall, the company’s financial performance reflects a strong cash position and effective cost management, which positions it for continued growth and advancement in its clinical programs.
Out of 912 hedge funds tracked by Insider Monkey in the second quarter, 31 had stakes in Janux Therapeutics (NASDAQ:JANX) with positions worth $974.191 million. As of June 30, RA Capital Management has a position worth $383.949 million in the company, making it the most prominent shareholder.
Overall JANX ranks 7th on our list of the hot stocks to buy. While we acknowledge the potential of JANX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than JANX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
Read Next: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.